5. Bivariate analyses for on study mortality in all cancer patients.
| On study mortality for all cancer patients | N included | ESA versus control Unadjusted HR (95% CI) | ESA versus control Adjusted HR (95% CI) |
P value LR‐Test |
| Total | 13933 | 1.17 (95% CI 1.06‐1.30) | ‐ | ‐ |
| Hb at baseline (continuous) | 13407 | 1.17 (95% CI 1.06‐1.30) | 1.18 (95% CI 1.07‐1.31) | 0.0000 |
| Hb at baseline (categorical 1) | 13407 | 1.17 (95% CI 1.06‐1.30) | 1.18 (95% CI 1.06‐1.31) | 0.0000 |
| Hb at baseline (categorical 2) | 13407 | 1.17 (95% CI 1.06‐1.30) | 1.18 (95% CI 1.07‐1.31) | 0.0000 |
| Tumor (categorical 1) | 13891 | 1.17 (95% CI 1.06‐1.30) | 1.17 (95% CI 1.06‐1.30) | 0.0000 |
| Tumor (categorical 2) | 13891 | 1.17 (95% CI 1.06‐1.30) | 1.16 (95% CI 1.05‐1.29) | 0.0000 |
| Sex | 13933 | 1.17 (95% CI 1.06‐1.30) | 1.16 (95% CI 1.05‐1.29) | 0.0000 |
| Age (continuous) | 13921 | 1.17 (95% CI 1.06‐1.30) | 1.17 (95% CI 1.06‐1.30) | 0.0007 |
| Age (categorical) | 13921 | 1.17 (95% CI 1.06‐1.30) | 1.18 (95% CI 1.06‐1.30) | 0.0160 |
| Hct (continuous) | 11036 | 1.18 (95% CI 1.06‐1.31) | 1.19 (95% CI 1.07‐1.32) | 0.0000 |
| Hct (categorical) | 11036 | 1.18 (95% CI 1.06‐1.31) | 1.19 (95% CI 1.07‐1.33) | 0.0000 |
| Baseline serum EPO (cont.) | 5651 | 1.11 (95% CI 0.95‐1.29) | 1.10 (95% CI 0.95‐1.28) | 0.1798 |
| Baseline serum EPO (cat.) | 5651 | 1.11 (95% CI 0.95‐1.29) | 1.10 (95% CI 0.95‐1.28) | 0.0006 |
| ECOG (0 vs 1 vs 2 vs 3 vs 4) | 10112 | 1.19 (95% CI 1.06‐1.33) | 1.17 (95% CI 1.05‐1.32) | 0.0000 |
| ECOG (0,1,2 vs 3,4) | 10225 | 1.18 (95% CI 1.06‐1.33) | 1.19 (95% CI 1.06‐1.34) | 0.0000 |
| BMI (categorical) | 11445 | 1.16 (95% CI 1.04‐1.30) | 1.17 (95% CI 1.04‐1.31) | 0.0000 |
| History of thromboembolic events | 9620 | 1.20 (95% CI 1.06‐1.34) | 1.19 (95% CI 1.06‐1.34) | 0.1105 |
| History of cardiovascular events | 10322 | 1.20 (95% CI 1.06‐1.34) | 1.19 (95% CI 1.06‐1.34) | 0.1002 |
| History of hypertension | 9620 | 1.20 (95% CI 1.06‐1.34) | 1.20 (95% CI 1.06‐1.34) | 0.8464 |
| History of diabetes mellitus | 8025 | 1.20 (95% CI 1.06‐1.35) | 1.20 (95% CI 1.06‐1.35) | 0.4497 |
| Geographical region [region_cat] | 13532 | 1.17 (95% CI 1.05‐1.29) | 1.16 (95% CI 1.05‐1.29) | 0.0001 |
| Metastatic vs non‐metastatic | 12152 | 1.21 (95% CI 1.09‐1.35) | 1.21 (95% CI 1.08‐1.35) | 0.0000 |
| Time from cancer diagnosis to randomization | 4586 | 1.17 (95% CI 0.99‐1.39) | 1.18 (95% CI 1.00‐1.40) | 0.0000 |